A new immunoglobulin preparation for topical administration in the eye
has been developed. The tolerance to this preparation was tested in a
phase I/II study, in combination with the antiviral drug trifluorothy
midine, in 5 patients with untreated episodes of herpes simplex epithe
lial keratitis. The clinical course of these patients was within usual
limits, with a mean healing time of 6.6 days (range 2-15 days). No un
desirable effects were observed. Our findings suggest that this new tr
eatment modality is safe and offers a new perspective, but additional
studies are required to determine its efficacy.